On June 23, Innovent Biologics rose 3.32% in regular trading, trading at 78.4 HKD/share, with turnover of HKD 268 million.

On the news front, the company announced that IBI3003, a trispecific antibody targeting GPRC5D/BCMA/CD3 for the treatment of multiple myeloma, has completed first patient dosing in its pivotal Phase III clinical trial. This milestone marks a critical step toward clinical application of the innovative therapy in second-to-fifth-line multiple myeloma patients.

Simultaneously, the biotech sector staged a broad rebound, providing additional support. Within the sector, Akeso rose 5.12%, Remegen gained 4.49%, and BeiGene advanced 3.91%. Furthermore, Xingye Securities maintained its Buy rating on Innovent, citing strong IBI363 first-line data presented at ASCO and the companys internationalization prospects through its partnership with Pfizer, which carries a total deal value of up to USD 10.5 billion including milestones and sales royalties.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)